Last reviewed · How we verify
Placebo to tulisokibart — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo to tulisokibart (Placebo to tulisokibart) — Merck Sharp & Dohme LLC. Placebo to tulisokibart does not have an active pharmacological mechanism as it is a placebo.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo to tulisokibart TARGET | Placebo to tulisokibart | Merck Sharp & Dohme LLC | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo to tulisokibart CI watch — RSS
- Placebo to tulisokibart CI watch — Atom
- Placebo to tulisokibart CI watch — JSON
- Placebo to tulisokibart alone — RSS
Cite this brief
Drug Landscape (2026). Placebo to tulisokibart — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-tulisokibart. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab